Controversial drug approval stokes concern about lack of a permanent FDA chief
Janet Woodcock did not release a statement with the approval — noteworthy considering it was the first new Alzheimer’s drug in nearly two decades.
Today's Liberal News
By Sarah Owermohle, Adam Cancryn and Lauren Gardner
Controversial drug approval stokes concern about lack of a permanent FDA chief
Janet Woodcock did not release a statement with the approval — noteworthy considering it was the first new Alzheimer’s drug in nearly two decades.
Controversial drug approval stokes concern about lack of a permanent FDA chief
Janet Woodcock did not release a statement with the approval — noteworthy considering it was the first new Alzheimer’s drug in nearly two decades.